Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

George Blanck

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1664-0996; OpenAlex author ID A5029216876. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 5

  1. Better pancreatic adenocarcinoma outcomes linked to anti-EBV TCR CDR3 detection via tumor RNAseq files. Last author DOI 10.1016/j.humimm.2025.111633↗
  2. Amplification of pro-proliferative genes adjacent to the F3 gene in pancreatic adenocarcinoma is associated with worse outcomes. Last author DOI 10.1080/15384101.2026.2674084↗
  3. The presence of intratumoral Porphyromonas gingivalis correlates with a previously defined pancreatic adenocarcinoma, immune cell expression phenotype and with… Last author DOI 10.1093/carcin/bgad033↗
  4. Apigenin Targets MicroRNA-155, Enhances SHIP-1 Expression, and Augments Anti-Tumor Responses in Pancreatic Cancer. Co-author DOI 10.3390/cancers14153613↗
  5. Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. Last author DOI 10.1007/s12307-018-0205-5↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sreenidhi Nidamanur · 1 shared paper, 2026 · strength 0.39
  2. Madeline C. Baker · 1 shared paper, 2026 · strength 0.32
  3. Jacob C. Kinskey · 2 shared papers, 2018–2023 · strength 0.30
  4. Tomar Ghansah · 1 shared paper, 2022 · strength 0.14
  5. Krystal Villalobos-Ayala · 1 shared paper, 2022 · strength 0.14
  6. Kazim M. Husain · 1 shared paper, 2022 · strength 0.14
  7. Clayton Yates · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.